Glaxosmithkline Pharmaceuticals Ltd share price logo

Glaxo Share Price

NSE: GLAXO

BSE: 500660

Mid Cap

Healthcare Sector

2733.50

-8.50

(-0.31%)

as on

bell
The current prices are delayed by 15 mins, login to check live prices.

Glaxo Stock Performance

as on September 18, 2025 at 12:01 pm IST

  • Day's Low

    Day's High

    ₹2,719.9
    ₹2,759
    downward going graph

    0.50%

    Downside

    0.93%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    ₹1,921
    ₹3,515.7
    downward going graph

    29.72%

    Downside

    28.62%

    Upside

    downward going graph

Glaxo share price movements today

Previous Close
₹2,742.00
Open
₹2,731.80
Volume
61.02K
Upper Circuit
₹3,290.40
Lower Circuit
₹2,193.60
Day's Low - High
₹2,719.9 - ₹2,759
52 Week Low - High
₹1,921 - ₹3,515.7

Glaxo Historical Returns

1 Month Return
-1.86 %
3 Month Return
-16.57 %
1 Year Return
-1.77 %
3 Year Return
+ 94.66 %
5 Year Return
+ 61.49 %

Glaxo Fundamentals

as on September 18, 2025 at 12:01 pm IST

Market Cap

₹46,451.13 Cr

Return on Equity (ROE)

49.23

PE Ratio (TTM)

49.09

Return on capital employed (ROCE)

58.72

Industry PE ratio

42.21

Beta (LTM)

0.78

P/B Ratio

25.01

Dividend Yield

1.88

PEG Ratio

4.46

Quarterly Earnings Growth YOY

12.44

EPS (TTM)

54.76

Sector

Pharmaceuticals

Book Value

115.19

Technical Analysis

Glaxo Stock Valuation

as on September 18, 2025 at 12:01 pm IST

Glaxo in the last 5 years

  • Overview

  • Trends

Lowest (-81.64x)

December 28, 2020

Industry (42.21x)

September 17, 2025

Today (49.09x)

September 17, 2025

Highest (333.07x)

September 15, 2020

LowHigh

Today’s Price to Earnings Ratio: 49.09x

Glaxosmithkline Pharmaceuticals Ltd vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Glaxo with its industry peers.

Company
Analyst View
Market Cap(in ₹ Cr)
5 Year CAGRDebt to Asset Ratio
Net Profit(in ₹ Cr)
Yearly Revenue(in ₹ Cr)
BUY46,451.1312.3%0.569273,749
BUY11,633.60-8.08%0.524132,013
BUY64,201.296.46%0.603,48331,723
HOLD1,04,024.4730.47%0.614,61423,241
BUY65,811.2517.53%0.001,4146,445

Analyst Recommendation on Glaxo Stock

Based on 4 analysts

BUY

50.00%

Buy

25.00%

Hold

25.00%

Sell

Based on 4 analysts, 50% of analysts recommend a 'BUY' rating for Glaxo. Average target price of ₹3094.75

Source: S&P Global Market Intelligence

Glaxo Share Price Target

Get share price movements and forecasts by analysts on Glaxo.

What analysts predicted

12.86%UPSIDE

Target Price

₹3094.75

Current Price

₹2733.5

Analyzed by

4 Analysts

High

₹3500

Target

₹3094.75

Low

₹2600

Glaxo target price 3094.75, a slight upside of 12.86% compared to current price of ₹2733.5. According to 4 analysts rating.

Source: S&P Global Market Intelligence

Glaxosmithkline Pharmaceuticals Ltd Quarterly Profit & Loss

Figures in Rupees Crores

Sep 2022
Dec 2022
Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sales
916.87
802.3
787.45
761.66
956.99
805.26
929.8
814.65
1,010.77
949.42
974.37
805.17
Other Income
21.97
23.42
38.06
53.74
28.21
28.11
32.23
35.64
39.23
35.07
40.68
43.72
Total Income
938.84
825.72
825.51
815.4
985.2
833.37
962.03
850.29
1,050
984.49
1,015.05
848.89
Expenses
659.94
584.97
617.71
617.78
667.5
750.51
672.54
584.11
689.06
657.5
641.18
553.97
Operating Profit
256.93
217.33
169.74
143.88
289.49
54.75
257.26
230.54
321.71
291.92
333.19
251.2
Operating Profit Margin %
28.02%
27.09%
21.56%
18.89%
30.25%
6.8%
27.67%
28.3%
31.83%
30.75%
34.2%
31.2%
Profit Before Interest, Tax and Depreciation
278.9
240.75
207.8
197.62
317.7
82.86
289.49
266.18
360.94
326.99
373.87
294.92
Interest
0.39
0.09
0.65
0.28
0.43
0.32
0.77
0.37
0.27
0.09
0.58
0.42
Depreciation
16.36
16.41
17.18
16.36
18.11
17.11
18.1
16.41
16.86
18.8
14.72
15.52
Profit Before Tax
262.15
224.25
189.97
180.98
299.16
65.43
270.62
249.4
343.81
308.1
358.57
278.98
Tax Paid
68.73
59.69
56.54
48.73
81.65
19.71
76.14
67.07
91.31
78.22
95.7
73.97
Profit After Tax
193.42
164.56
133.43
132.25
217.51
45.72
194.48
182.33
252.5
229.88
262.87
205.01
Total Net profit including share of profit / Loss from associate company
193.42
164.56
133.43
132.25
217.51
45.72
194.48
182.33
252.5
229.88
262.87
205.01
EPS
11.42
9.71
7.41
7.04
12.84
9.89
11.37
10.76
14.67
13.57
15.52
12.1
Actual EPS
11.42
9.71
7.41
7.04
12.84
9.89
11.37
10.76
14.67
13.57
15.52
12.1
Adjusted EPS
11.42
9.71
7.41
7.04
12.84
9.89
11.37
10.76
14.67
13.57
15.52
12.1
Diluted EPS
11.42
9.71
7.88
7.81
12.84
2.7
11.48
10.76
14.91
13.57
15.52
12.1

Glaxosmithkline Pharmaceuticals Ltd Annual Profit & Loss

Figures in Rupees Crores

Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Sales
2,908.47
2,871.46
3,128.12
3,224.38
2,925.6
3,278.03
3,251.72
3,453.71
3,749.21
Other Income
118.8
72.34
131.01
79.01
181.46
1,401.31
103.71
122.59
150.62
Total Income
3,027.27
2,943.8
3,259.13
3,303.39
3,107.06
4,679.34
3,355.43
3,576.3
3,899.83
Expenses
2,489.48
2,365.65
2,527.33
2,908.62
2,500.06
2,516.15
2,448.4
2,688.63
2,571.85
Operating Profit
418.99
505.81
600.79
315.76
425.54
761.88
803.32
765.08
1,177.36
Operating Profit Margin %
14.41%
17.62%
19.21%
9.79%
14.55%
23.24%
24.7%
22.15%
31.4%
Profit Before Interest, Tax and Depreciation
537.79
578.15
731.8
394.77
607
2,163.19
907.03
887.67
1,327.98
Interest
0.25
0.19
0.55
6.34
3.53
2
1.81
1.8
1.31
Depreciation
26.35
37.99
48.59
82.68
78.6
68.19
65.77
69.68
66.79
Profit Before Tax
511.19
539.97
682.66
305.75
524.87
2,093
839.45
816.19
1,259.88
Tax Paid
174.37
189.25
237.27
212.55
166.72
398.28
228.76
226.23
332.3
Profit After Tax
336.82
350.72
445.39
93.2
358.15
1,694.72
610.69
589.96
927.58
Total Net profit including share of profit / Loss from associate company
336.82
350.72
445.39
93.2
358.15
1,694.72
610.69
589.96
927.58
EPS
39.76
41.41
26.29
5.5
21.14
100.04
36.08
41.14
54.52
Actual EPS
39.76
41.41
26.29
5.5
21.14
100.04
36.08
41.14
54.52
Adjusted EPS
19.88
20.71
26.29
5.5
21.14
100.04
36.08
41.14
54.52
Diluted EPS
39.76
41.41
26.29
5.5
21.14
100.04
36.05
34.83
54.76

Glaxosmithkline Pharmaceuticals Ltd Cash Flow

Figures in Rupees Crores

Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Net Cash from Operating Activities
138.9
234.37
472.8
409.49
490.5
577.91
810.75
484.23
582.02
1,289.9
Cash Flow from Investing Activities
499.02
300.64
-104.19
-153.45
-56.84
418.02
-405.51
807.85
8.72
-45.8
Cash Flow from Financing Activities
-638.33
-510.76
-306.64
-358.36
-427.62
-695.55
-524.24
-1,543.33
-561.5
-769.42
Net Cash Flow
-0.42
24.24
61.97
-102.33
6.03
300.38
-119
-251.25
29.23
474.68

Glaxo Stock Shareholding Pattern

Numbers in percentages

Dec 2022
Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Promoters
75%
75%
75%
75%
75%
75%
75%
75%
75%
75%
75%
DII
10.28%
10.3%
10.23%
10.01%
8.53%
7.9%
7.5%
7.34%
7.3%
7.79%
7.7%
FII
0%
0%
0%
0%
0%
3.48%
4.02%
4.36%
4.5%
4.52%
4.89%
Government
0%
0%
0%
0.01%
0.01%
0%
0%
0%
0%
0%
0%
Public
12.43%
12.43%
12.34%
12.48%
13.43%
13.62%
13.48%
13.3%
13.19%
12.69%
12.41%
Total Outstanding Shares
16,94,06,034
16,94,06,034
16,94,06,034
16,94,06,034
16,94,06,034
16,94,06,034
16,94,06,034
16,94,06,034
16,94,06,034
16,94,06,034
16,94,06,034
Total Shareholders
1,20,127
1,20,415
1,19,032
1,15,266
1,14,663
1,18,994
1,18,515
1,19,228
1,19,625
1,21,885
1,23,629

Mutual Funds that own Glaxo Stock

Check out the Mutual Funds with significant holdings in Glaxo.

Glaxo Earnings and Dividends

View detailed summary of the earnings and dividend history of Glaxo.

  • Glaxosmithkline Pharmaceuticals Ltd Earnings Results

    Glaxosmithkline Pharmaceuticals Ltd’s net profit jumped 12.44% since last year same period to ₹205.01Cr in the Q1 2025-2026. On a quarterly growth basis, Glaxosmithkline Pharmaceuticals Ltd has generated -22.01% fall in its net profits since last 3-months.

    Read More about Earnings Results
  • Glaxosmithkline Pharmaceuticals Ltd Dividends May,2025

    In the quarter ending March 2025, Glaxosmithkline Pharmaceuticals Ltd has declared dividend of ₹42.00 per share on 13 May 2025 - translating a dividend yield of 3.14%.

    Read More about Dividends

Indices Featuring Glaxo Stock

Check stock indices that include Glaxo.

S&P BSE Quality

₹1,880.07

0.16 (3.02%)

BSE Mid-Cap

₹46,777.74

0.08 (35.72%)

Nifty LargeMidcap 250

₹16,494.60

0.18 (29%)

Nifty MidSmallcap 400

₹20,287.15

0.05 (10%)

BSE 200

₹11,535.66

0.28 (32.58%)

S&P BSE 250 LargeMidCap

₹10,963.90

0.29 (31.56%)

S&P BSE 150 MidCap

₹16,343.73

0.08 (13.39%)

Nifty 500

₹23,500.35

0.24 (55.15%)

S&P BSE 400 MidSmallCap

₹12,294.77

0.03 (3.17%)

BSE Healthcare

₹44,827.03

0.2 (88.3%)

BSE 500

₹36,905.78

0.25 (92.65%)

Nifty Midcap 150

₹21,840.20

0.04 (9.15%)

Insights on Glaxosmithkline Pharmaceuticals Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    FII Holding Up

    img

    Foreign Institutions have increased holdings from 4.52% to 4.88% in Jun 2025 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Torrent Pharmaceuticals Ltd has given 139.7% return, outperforming this stock by 45.0%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Divis Laboratories Ltd has given 10.7% return, outperforming this stock by 12.4%

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 75.00% of holdings in Jun 2025 quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, GLAXO stock has moved down by -4.3%

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 12.69% to 12.41% in Jun 2025 quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 262.87 Cr → 205.01 Cr (in ₹), with an average decrease of 22.0% per quarter

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 1.01K Cr → 848.89 Cr (in ₹), with an average decrease of 16.4% per quarter

About Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UKbased GSK Plc. a global biopharma company to unite science technology and talent to get ahead of disease together. The Company is headquartered in Mumbai and it has six branch offices a manufacturing facility at Nashik in Maharashtra 22 contract manufacturing organisations CMOs with regional and sales hubs across India. The Company is engaged interalia in the business of manufacturing distributing and trading in pharmaceuticals.The Companys portfolio includes General Medicines Vaccines and Specialty medicines that help prevent and treat disease. Their prescription medicines range across therapeutic areas such as AntiInfectives Dermatology Gynaecology Diabetes Oncology Cardiovascular Disease and Respiratory Diseases. They also offer a range of vaccines for the prevention of Hepatitis A Hepatitis B Invasive Disease caused by H Influenza Chickenpox Diphtheria Pertussis Tetanus Rotavirus Cervical Cancer and Others. They have two manufacturing units in India located at Nashik and Thane. Also they have a clinical development centre in Bangalore. GlaxoSmithKline Pharma Limited was incorporated in November 13 1924. During year 1956 the Company began primary production of vaccines at Worli. In the year 1960 the company started manufacturing Infant foods at milk drying plant at Aligarh. They also opened manufacturing facility for pharmaceuticals in Mumbai. In 1961 the Company started manufacturing Vitamin A and Betamethasone at new plant at Thane using imported raw materials. The Company registered as a limited company in the year 1968. Also they introduced the Animal health products. In the year 1971 the company built the Research development laboratory at Thane. Also they relocated the SmithKline French plant from Mumbai to Bangalore. In the year 1983 they commissioned the Nashik factory. SmithKline Beecham became a public limited company under the new name of Eskayef Ltd in the year 1984 and one new Plant was set up in Mysore for manufacture of bulk drugs. In the year 1985 the companys second basic drugs factory was inaugurated at Ankleshwar Gujarat. In the year 1986 the company launched joint venture projects Vegepro Foods and Feeds Ltd and K G Gluco Biols. The companys name was changed to Glindia Ltd in the year 1987. In the year 1988 the company commenced the production of bulk drug Ranitidine at Ankleshwar. Also they started a joint venture project with Hindustan Foods Ltd for the manufacture of extruded foods at Usgao Goa. In the year 1989 the company commenced their Zinetac production at Nashik. The companys name was changed from Glindia Ltd to Glaxo India Ltd. In the year 1990 the production of the bulk drug cephalexin was commenced at Ankleshwar and the salbutamol inhalers at Nashik. Glaxo rated amongst the first five of Indias most respected companies 4th place in a survey by Businessworld magazine. An agreement was signed with the Council of Scientific and Industrial Research CSIR during 1991. In the year 1992 the company sold their trade investments in Vegepro and Feeds Ltd. In the year 1993 they sold their investment in Hindustan Foods Ltd and Dempo Dairy Industries Ltd. Cetzine a secondgeneration antihistamine and research product of UCB Pharma Belgium was launched under a comarketing agreement. In the same year Glaxo received recognition from the Ministry of Commerce as an export house. In the year 1994 the company sold their Family Products Division to H J Heinz for a sum of Rs 210 crore. The Mysore plant received ISO 9002 certification and the new Iodex plant was inaugurated in Bangalore. In the year 1995 they inaugurated the government approved stateoftheart Pharmacy Research Development Centre PRD at Thane to cater to the unmet medical needs and to exploit local commercial opportunities.In the year 1998 the company acquired Biddle Sawyer Group of Companies which was struggled in the year before. In the year 2000 Agrivet Farm Care AFC tied up with Merial the worlds largest Animal Health Company to market poultry vaccines. The company ranked 6th in Business Today Stern Stewart Co. listing of Indias best Wealth Creator Companies and also the launched Seretide for Asthma. The merger of SmithKline Beecham Pharmaceuticals India Ltd into Glaxo India Limited was completed and the name of the company was changed to the present name GlaxoSmithKline Pharmaceuticals Ltd. Businessworld and the Indian Market Research Bureau IMRB named GlaxoSmithKline as Indias most respected Pharmaceutical Company in a survey in the year 2003. During the year the company launched Cetzine Cetirizine antihistamine Zimig terbinafine antiinfective CCM calcium citrate maleate nutritional Cobadex CZS multivitamin with trace elements.In the year 2004 the company launched Priorix measles mumps rubella vaccine. In the year 2005 the company launched oral contraceptives: Elogen desogestrel and ethinylestradiol and Zerogen progesterone only pill. They entered into the diabetes therapeutic segment with the launch of Windia rosiglitazone and Windamet rosiglitazone and metformin. In the year 2006 the company made an inlicensing alliance with Eisai Pharmaceuticals Japan and launched Parit rabeprazole gastrointestinal therapy area. Also GlaxoSmithKline divested their Agrivet Farm Care AFC animal health business. In the year 2007 the company launched Carzec carvedilol and Zemetril cefprozil.

Revenue: ₹805.17Cr as on June 2025 (Q1 FY26)
Net Profit: ₹205.01Cr as on June 2025 (Q1 FY26)
Listing date: 03 Nov, 1994
Chairperson Name: Renu S Karnad
OrganisationGlaxosmithkline Pharmaceuticals Ltd
IndustryPharmaceuticals
CEORenu S Karnad
E-voting on sharesClick here to vote

FAQs

What is Glaxo share price today?

Glaxo share price today stands at ₹2733.5 as on . Glaxo share today touched a day high of ₹2759 and a low of ₹2719.9.

What is the 52 week high and 52 week low range for Glaxo share?

Glaxo touched a 52 week high of ₹3515.7 and a 52 week low of ₹1921. Glaxo share price today i.e. is trending at ₹2733.5, which is -22.25% down from its 52 week high and 42.30% up from its 52 week low.

What is Glaxo's market capitalisation today?

Glaxo market capitalisation is ₹46,451.13 Cr as on .

How to buy Glaxo shares?

To buy Glaxo shares, you need to follow these steps:

  • Open a Demat account and Trading account on INDmoney
  • Fund your Trading account
  • Search for GLAXO or Glaxosmithkline Pharmaceuticals Ltd on the INDmoney app to check live prices of the stock
  • Click on Buy or SIP to place an order to invest in Glaxo shares. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.

What is Glaxo trading volume today?

Glaxo trading volume is 61.02K as on . This means that 61.02K shares of Glaxo were bought and sold on the stock market during today's trading session.